Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Cash from Operations (2020 - 2025)

Historic Cash from Operations for Mirum Pharmaceuticals (MIRM) over the last 6 years, with Q3 2025 value amounting to $39.7 million.

  • Mirum Pharmaceuticals' Cash from Operations rose 89600.9% to $39.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $44.7 million, marking a year-over-year increase of 374832.65%. This contributed to the annual value of $10.3 million for FY2024, which is 11455.37% up from last year.
  • Mirum Pharmaceuticals' Cash from Operations amounted to $39.7 million in Q3 2025, which was up 89600.9% from $12.0 million recorded in Q2 2025.
  • Mirum Pharmaceuticals' Cash from Operations' 5-year high stood at $39.7 million during Q3 2025, with a 5-year trough of -$40.2 million in Q2 2021.
  • In the last 5 years, Mirum Pharmaceuticals' Cash from Operations had a median value of -$18.2 million in 2023 and averaged -$13.9 million.
  • As far as peak fluctuations go, Mirum Pharmaceuticals' Cash from Operations crashed by 13654.82% in 2021, and later soared by 89600.9% in 2025.
  • Over the past 5 years, Mirum Pharmaceuticals' Cash from Operations (Quarter) stood at -$33.1 million in 2021, then fell by 3.39% to -$34.3 million in 2022, then soared by 51.51% to -$16.6 million in 2023, then surged by 69.5% to -$5.1 million in 2024, then surged by 882.97% to $39.7 million in 2025.
  • Its Cash from Operations stands at $39.7 million for Q3 2025, versus $12.0 million for Q2 2025 and -$2.0 million for Q1 2025.